Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2015-005642-59-DK
EUCTR2015-005642-59-DK
Active, not recruiting
Phase 1

Phase II trial: uPAR-PET for prognostication in patients with non-small cell lung cancer, malignant pleural mesothelioma and large cell neuroendocrine carcinoma of the lung

Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET0 sitesJanuary 21, 2016
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionson-small cell lung cancer, malignant pleural mesothelioma, large cell neuroendocrine carcinoma of the lungMedDRA version: 18.1Level: PTClassification code 10057270Term: Neuroendocrine carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10059518Term: Pleural mesothelioma malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
on-small cell lung cancer, malignant pleural mesothelioma, large cell neuroendocrine carcinoma of the lung
Sponsor
Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET
Status
Active, not recruiting
Last Updated
8 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 21, 2016
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET

Eligibility Criteria

Inclusion Criteria

  • •\- Histologically verified NSCLC
  • •\- Stage IV disease
  • •\- Operable disease
  • •\- Age above 18
  • •\- The participants must be capable of understanding and giving full informed written consent
  • •\- Histologically verified MPM
  • •\- Age above 18
  • •\- The participants must be capable of understanding and giving full informed written consent
  • •\- Histologically verified LCNEC
  • •\- Age above 18

Exclusion Criteria

  • •Study I, II, III:
  • •\- Pregnancy
  • •\- Lactation/breast feeding
  • •\- Age above 85 years
  • •\- Weight above 140 kg
  • •\- Treatment with neoadjuvant chemotherapy
  • •\- Allergy to 68Ga\-NOTA\-AE105

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
uPAR-PET/CT for prognostication in head- and neck cancerHead and neck cancerMedDRA version: 19.0Level: HLTClassification code 10026660Term: Malignant oral cavity neoplasmsSystem Organ Class: 100000004856MedDRA version: 19.0Level: HLTClassification code 10028801Term: Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecifiedSystem Organ Class: 100000004864MedDRA version: 19.0Level: HLTClassification code 10023826Term: Laryngeal neoplasms malignantSystem Organ Class: 100000004864Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]
EUCTR2016-002082-65-DKAndreas Kjaer
Active, not recruiting
Phase 1
uPAR-PET - a new method for determining lymph node metastases in breast cancer patientsbreast cancerMedDRA version: 18.1Level: LLTClassification code 10006192Term: Breast cancer NOSSystem Organ Class: 100000004864Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]
EUCTR2015-004503-23-DKRigshospitalet, Department of Clinical Physiology, Nucelar Medicine and PET
Active, not recruiting
Phase 1
uPAR-PET/MRI in patients with prostate cancer for evaluation of tumor aggressiveness
EUCTR2017-002276-37-DKRigshospitalet, Department of Clinical Physiology, Nuclear Medicine & PET52
Active, not recruiting
Phase 1
uPAR PET/CT og FDG PET/CT til præoperativ stadieinddeling af patienter med nydiagnosticeret Gynækologisk Kræftgynecological cancers:Vulvar cancerendometrial cancer (uterine cancer)cervical cancerovarian cancerMedDRA version: 20.0Level: LLTClassification code 10007107Term: Cancer of ovarySystem Organ Class: 100000021045MedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 100000020935MedDRA version: 20.0Level: LLTClassification code 10047743Term: Vulval cancer NOSSystem Organ Class: 100000021101MedDRA version: 20.0Level: LLTClassification code 10007063Term: Cancer of endometriumSystem Organ Class: 100000021008MedDRA version: 20.0Level: LLTClassification code 10008229Term: Cervical cancerSystem Organ Class: 100000020977Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]
EUCTR2016-004638-99-DKRigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET350
Active, not recruiting
Phase 1
Phase II trial: uPAR PET/CT and FDG PET/MRI for determining lymph node metastases in patients with bladder cancerrinary bladder cancerMedDRA version: 19.0Level: LLTClassification code 10005004Term: Bladder cancer NOSSystem Organ Class: 100000004864Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]
EUCTR2016-001026-33-DKRigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET40